Podcasts about hss

William B. Coley started using a bacterial infection to treat cancers in the late 19th century, one of the earliest uses of immunotherapy. Research: Ahuja, Sana and Sufian Zaheer. “The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.” Korean Journal of Clinical Oncology 2024; 20(2): 51-73. DOI: https://doi.org/10.14216/kjco.24009 Atkins, Douglas. “Helen Coley Nauts: Advocate for Immunotherapy.” National Library of Medicine. 4/19/2016. https://circulatingnow.nlm.nih.gov/2016/04/19/helen-coley-nauts-advocate-for-immunotherapy/ Cancer Research Institute. “The History of Cancer Immunotherapy.” Coley, William B. “Therapeutic Value of the Mixed Toxins of the Streptococcus of Erysipelas and Bacillus Prodigiosus in the Treatment of Inoperable Malignant Tumors. With a Report of 160 Cases.” American Journal of the Medical Sciences. September 1896. College of Physicians of Philadelphia. “Cancer Vaccines and Immunotherapy.” History of Vaccines. https://historyofvaccines.org/vaccines-101/future-immunization/cancer-vaccines-and-immunotherapy/ Colley, William B. “The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).” Reprinted from the “ Proceedings of the Royal Society of Medicine,” November, 1909. London. John Bale, Sons & Danielsson, LTD. 1909. https://archive.org/details/b22425949/mode/1up Decker WK, da Silva RF, Sanabria MH, Angelo LS, Guimarães F, Burt BM, Kheradmand F and Paust S (2017) Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front. Immunol. 8:829. doi: 10.3389/fimmu.2017.00829 Devaraja, K. et al. “Coley’s Toxin to First Approved Therapeutic Vaccine—A Brief Historical Account in the Progression of Immunobiology-Based Cancer Treatment.” Biomedicines 2024, 12, 2746. https://doi.org/10.3390/biomedicines12122746 Dobosz, Paula and Tomasz Dzieciatkowski.” The Intriguing History of Cancer Immunotherapy. Frontiers in Immunology. 12/17/2019. doi: 10.3389/fimmu.2019.02965 Hall, Stephen S. “A Commotion in the Blood: Life, Death, and the Immune System.” Henry Holt and Company. Excerpted at New York Times. https://archive.nytimes.com/www.nytimes.com/books/first/h/hall-commotion.html Harutyunyan, Mariam. “How William Coley Became The Father of Cancer Immunotherapy.” OncoDaily Magazine. 7/31/2026. https://oncodaily.com/magazine/william-coley-549446 Hiroaki Ikeda, Cancer immunotherapy in progress—an overview of the past 130 years, International Immunology, Volume 37, Issue 5, May 2025, Pages 253–260, https://doi.org/10.1093/intimm/dxaf002 Journal of the American Medical Association. “Erysipelas Toxins in the Treatment of Malignant Tumors.” 10/27/1894. Journal of the American Medical Association. “The Failure of the Erysipelas Toxins.” Vol 23 Iss 24. 12/15/1894. Kokolus, Katie. “The History of Immunotherapy: Toxins, Targets & T Cells.” LabRoots. 10/18/2021. https://www.labroots.com/trending/cancer/21449/history-immunotherapy-toxins-targets-cells?srsltid=AfmBOooP1eoVP2LbWKR5m-HLu1PSBFhOyPH1jSJWWcxvyK6EA4-hBu47 Levine, David B. “The Hospital for the Ruptured and Crippled: William Bradley Coley, third Surgeon-in-Chief 1925-1933.” HSS journal : the musculoskeletal journal of Hospital for Special Surgery vol. 4,1 (2008): 1-9. doi:10.1007/s11420-007-9063-2 McCarthy, Edward F. “The Toxins of William B. Coley and the Treatment of Bone and Soft-tissue Sarcomas.” The Iowa Orthopaedic Journal. Vol. 26. Memorial Sloan Kettering Cancer Center. “MSK Immunotherapy — Timeline of Progress.” https://www.mskcc.org/timeline/immunotherapy-msk National Library of Medicine. “Harnessing the Power of You: The History of Immunotherapy.” https://www.nlm.nih.gov/exhibition/the-history-of-immunotherapy/index.html Nauts, Helen Coley. “Coley’s Toxins – The First Century.” Townsend Letter for Doctors and Patients. June 2004. Nawrat, Allie. “Charting the history of immunotherapy, cancer treatment’s fourth pillar.” Pharmaceutical Technology. 7/28/2020. https://www.pharmaceutical-technology.com/features/charting-the-history-of-immunotherapy-cancer-treatments-fourth-pillar/?cf-view&cf-closed Oiseth SJ, Aziz MS. “Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead.” J Cancer Metastasis Treat. 2017;3:250-61. http://dx.doi.org/10.20517/2394-4722.2017.41 Tontonoz, Matthew. “What Ever Happened to Coley’s Toxins?.” Cancer Research Institute. 4/2/2015. https://www.cancerresearch.org/blog/what-ever-happened-to-coleys-toxins See omnystudio.com/listener for privacy information.

En este podcast respondo algunas de las preguntas que más me hacéis sobre fotografía, iluminación, objetivos y cómo ganarse la vida como fotógrafo profesional.Hablamos de si un flash pequeño realmente sirve para hacer retratos en exteriores y al atardecer, y de por qué la potencia del flash no lo es todo. Distancia al sujeto, modificadores, tamaño de la fuente de luz, ISO, HSS… hay muchas más variables de las que parece.También explico una duda muy habitual sobre medición puntual y medición matricial: qué ocurre después de calcular correctamente la exposición y por qué puedes cambiar el modo de medición sin cargarte la foto si estás trabajando en manual.Además, respondo a una comparación entre el Viltrox 56mm f/1.2 y el Viltrox 27mm f/1.2. Dos objetivos espectaculares, pero que no deberían elegirse simplemente preguntando cuál tiene “más calidad”. Antes de comprar un objetivo tienes que tener claro qué distancia focal necesitas y para qué tipo de fotografía o vídeo vas a utilizarlo.Y sí… también me caliento un poco respondiendo a un comentario sobre la publicidad y los patrocinadores del podcast. Después de años creando contenido gratuito cada semana, tenía algunas cosas que decir sobre este tema.Por último, hablamos de una de las excusas que más escucho entre quienes quieren dedicarse profesionalmente a la fotografía: “en mi ciudad el mercado está saturado”. Para mí, que haya competencia no significa que no haya oportunidades. La clave está en diferenciarte, entender marketing, aprender a vender y encontrar qué puedes ofrecer tú que los demás no están ofreciendo.Si quieres dedicarte a la fotografía profesional, mejorar tu técnica o entender mejor cómo funciona realmente este negocio, creo que este podcast te va a dar unas cuantas ideas.Déjame también tus preguntas en los comentarios porque pueden convertirse en protagonistas de próximos programas.#Fotografia #FotografoProfesional #IluminacionFotografica #FlashFotografia #Viltrox #MarketingParaFotografos #PodcastFotografia**COMPRA EN FOTOK desde este enlace y pon el cupón GABELLIFTK en tu carrito de la compra para llevarte un regalo.WEB FOTOK: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://fotok.es/?aff=y206⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠___________________WEBS: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.rubengabelli.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://fotografodecomida.es⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YOUTUBE: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://cutt.ly/ft3QEHF ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠PATREON: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/RubenGabelli ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠INSTAGRAM: @rubengabelli

Dr. Andrew Holman is a rheumatologist and the CEO of Seattle-based Inmedix, which recently received FDA clearance for the first cloud-based heart rate variability (HRV) diagnostic platform. Dr. Holman shares how a “detective” mindset led him from early interests in orthopedics and cardiology into rheumatology, fibromyalgia research, and ultimately entrepreneurship. He explains how chronic stress, the autonomic nervous system, and conditions like sleep apnea and restless leg syndrome can influence cardiovascular risk and autoimmune disease outcomes, and why measuring stress biology with medical-grade precision matters. Dr. Holman also offers hard-earned advice for physician-innovators, reflects on pivotal study results, and shares what he hopes to be remembered for: never dismissing patients in distress.  Guest links: https://www.inmedix.com | https://www.linkedin.com/company/inmedix-inc Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 088 - Andrew Holman [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to be welcoming as my guest Dr. Andrew Holman. Dr. Holman is a rheumatologist and the CEO of Inmedix, a Seattle-based medical diagnostics company that recently received FDA clearance for the first cloud-based heart rate variability diagnostic platform. He has 25 years of clinical experience with 16 peer-reviewed papers and clinical trials demonstrating that measuring stress biology with medical grade precision can improve success rates in autoimmune diseases. All right. Andrew, welcome to the show. I'm so glad you're here today. [00:01:30] Andrew Holman: Yes, happy to be here. Thank you for inviting me. [00:01:33] Lindsey Dinneen: Course, of course. Well, I would love, if you wouldn't mind starting out telling us a little bit about who you are, what your background is, and what led you to medtech. [00:01:44] Andrew Holman: Sure. Well, I'm a, a guy from Seattle, Washington. Grew up here, but trained everywhere else, became a rheumatologist. We study autoimmune diseases, lupus, rheumatoid arthritis. I also was very interested in fibromyalgia and pain. We're the immunologists of medicine. So, I started my practice, golly, a while ago. 1992, I finished my prac- my training, and I was the main rheumatologist at a large suburban hospital at the southern end of Seattle. So hometown, circle back to the hometown. I went into rheumatology because you have many choices when you do internal medicine. You can go be a specialist in many things. But I like the puzzles. The immunology has grown and it's a, it's a particularly sort of detective-oriented specialty. So, I didn't set out to be an entrepreneur. That came 25 years later. I was an in-the-trenches doc trying to help the person in front of me with these devastating diseases that are crippling diseases, usually of young women mostly. [00:02:45] Lindsey Dinneen: Yeah. Okay, and I'm sure there's, there's much more we're gonna dive into, but one thing that really stood out really fast was you, you kind of called yourself a detective, which I really love that term. And so I'm curious, is that something that you always thought you wanted to specialize in, in medicine, or was this, you know, detectiving to come later? Was this something that, you know, you ended up learning more about while in med school and thought, "Oh, this sounds really cool. I could put really two interesting passions together"? [00:03:19] Andrew Holman: Yeah, it was-- you know, things just sort of come into play sometime. For those who are not in medicine, they may not realize it takes about ten years to go to college, med school, re- internship, residency, fellowship, you know, and then you, then you finally get to go be a doctor, and you have to go learn how to be a doctor s- a little more. The patients teach you a lot more than people realize. So I was gonna be an orthopedist. I liked orthopedics. I liked architecture, bones, joints. I thought it was a lot of fun. I just had very little aptitude for what they do. I, I don't-- I, I'm not very g- a good carpenter. I just, you know, I didn't-- just wasn't gonna be a great orthopedist. So then I thought, "I really love cardiology." Rhythm disturbances, all kinds of things. In the 1980s, when I was in medical school , all the new stents and procedures and non- less invasive things than bypass surgery were all coming up. Joint valve replacement. You know, it's really exciting. But I never... and I never took a, a f- a course in rheumatology until I was actually an intern in internal medicine program in Denver, all set to be a cardiologist. And there were 12 of us in the, in the program per year, and s- five of us became rheumatologists because of this one doctor who took us out, a guy named Daryl McCarter. Prob- maybe people who know him, he's retired recently. He would bring us in the office, and we'd see every other patient with him because in between the patients, he would give us an X-ray, say, "I want you to look at this. There's a clue here. See if you can find it." Or, "I want you to look at this pathology slide," or something. "There's a secret, you know, to figure this one out." And I go, "Wow, this is really fun stuff." And once you figured it out, we weren't as good at treating it yet, but we were getting better. We were getting better. So it was the cutting edge and very fertile ground for discovery. So, rheumatologists are called the consult of last resort for a reason. There aren't very many of us. You've usually seen everybody else first, and by the time they-- you see us, we're pretty good at figuring out the rare diseases that are not in other people's board exam. But we're also pretty good at figuring out the common disease that presents in a very strange way, you know? And, and that's what our strength is. So we may... Everybody who sees us who gets diagnosed may not have a rheumatology answer, but we try to get them an answer. And now we're really in the golden age of rheumatology in the last 20 years of really making a difference for so many people. The downside, we don't make a difference for enough people, you know? We, we... That's the problem. So we've got these very motivated doctors out there, eager, and we just need, you know, more. And that's why I became an entrepreneur, because I learned more neurology than I was supposed to know and more sleep physiology than I was supposed to know. You just follow the breadcrumbs, you know? [00:06:17] Lindsey Dinneen: Yeah. Okay, so I know you didn't start out wanting to, or maybe even being interested in being an entrepreneur, but that is the path that you chose, and I would love to hear about that, the company, and what you're all doing. And then also would love to hear about your journey into deciding that this is the next right step for me. [00:06:38] Andrew Holman: Yeah. Well, thanks for asking it. It is a little unusual. So I was actually studying and trying to help patients with fibromyalgia about 30 years ago. And fibromyalgia patients terribly dismissed till they're all making this up. There's not 10 million people that can make anything up and be consistent. I mean, they all say the same thing. So I thought that was nonsense, and I was really thrown into the crowd of, you know, "You're, you're crazy too." And I go, "Well, I'm board certified in crazy." So I w- I was interested in it, and I was irritated that these people were dismissed. And I was around other doctors in Seattle who were similarly that way, which was very, very unusual. It's unusual to find people in the '90s who had an avid interest in that disorder. And so I started doing what rheumatologists are good at, incrementally advancing ideas and therapeutics very carefully, very cautiously. We do a lot of things off-label. When I was-- finished my fellowship in 1992, half the diseases on our board exam had no FDA-approved treatment. We had to do something, right? You couldn't just say, "Well, come back when there's a couple of articles in the New England Journal of Medicine." You, you can't do that, right? People are depending on you. So rheumatologists are particularly good at that, and that's not something most doctors want to do. Most doctors find that very uncomfortable. They're very, very careful people. And, and rheumatologists are careful too, but we take this mission seriously that we need to do something for you. So basically, I was looking at off-label ideas and work on fibromyalgia, and I'll share this with your audience. I was actually pulled up-- pulled in by some senior doctors who said, "We wanna talk with you." And I'd been there about three years as a new doctor. Oh, you know, seem to be doing a good job. Maybe they wanna pat me on the back or something. No, not that. It was actually an intervention, which I had never... I mean, I had no familiarity with what an intervention was. And they said, "Look, we like you. You're a great doc, but you're gonna ruin your reputation if you believe all these people, mostly women And you really need to not take it so seriously or write prescriptions for this c-- this and that." I said, "Well, thank you very much." That's polite. That's not what I was thinking. And I, I... But it prompted me to pull all the charts and say, "You know, I think I'm making some progress here with some ideas here, and let me see if I'm getting fooled and just seeing the people who get better to come back. Let me really honestly look at my performance." And so I pulled about 200 charts. It was my first abstract at the national meeting. And you know what? We were making progress. That had morphed into more progress, following the breadcrumbs, looking at neurology, looking at the autonomic nervous system. So that was about a five-year process. Y-you know, I didn't lose my reputation, obviously. I lecture around the world now. But it led to being very careful about getting clinical evidence if I had a hypothesis. And so we were using the office, and we actually finally did a double-blind prospective study where I bought all the drug myself, had it reformulated, little capsules that, you know, and, and worked with the FDA to get permission to do the study. And that study in fibromyalgia to this day has the highest response rate of any fibromyalgia study for pain that's ever been done. Now, we don't use that treatment anymore. It's 20 years later, we have other things to do. But it did prompt Pharmacia, got bought by Pfizer, I believe, and Boehringer Ingelheim, which co-marketed the drug I was using and reporting on, to pay me $10 million for the patents that I had filed, utility patents. I didn't own the drug. I didn't use it for Parkinson's disease, but I thought there was use in fibromyalgia. So before I told the world, I filed utility patents, and they wanted to exploit that discovery. So did two other pharmaceutical companies, and they had to pay for the privilege of doing it. So at 46, I retired. So I didn't intend to do that, but I do come from a family of lawyers and judges, and so the idea of having a utility patent on a n- a new innovative idea was not a foreign concept to me. [00:10:40] Lindsey Dinneen: Yeah. [00:10:41] Andrew Holman: That is something I teach all young doctors. [00:10:46] Lindsey Dinneen: That is awesome, and I, I was thinking, okay, this is a great segue because first of all, that's an incredible story. Secondly, I, I would be very curious to know exactly that, what is your advice for some of these incredible physicians, great ideas, that are potentially going to end up becoming an entrepreneur just because that's the path that, that is sort of presented to them? What is some of your advice for that? 'Cause that can't just be... you, you had the privilege at least of, of, of knowing and having some background in that, the legal aspects of IP protection and whatnot, but what are some of the things that you tell people? [00:11:22] Andrew Holman: Well, a couple things I would say and I have these conversations often 'cause I really like the younger people coming along. I say, first of all, don't define yourself as an ent- as being an entrepreneur. Make sure you have other things in your life that are more important to you. Now, the investors are not gonna like to hear that. They, they want you to live and die on your, on your company, right? But I'm saying, you know, you don't have to tell the VCs, but have other things that matter more in your life. You still gotta work really hard because you may, you may find that it's really a slog, and it's very long, and it's very hard. But, you know, make sure that, that, that what you-- though is important, your family, you know, your integrity the scientific problem at hand, the patients, you know, they're number one. Make sure we don't lose sight of all that, and do a few things. Go for a walk. Do something for yourself. Something. I do this twenty-four seven for the last 10 years, you know, every day 'cause I love doing it. It does wear you out, though. Even if you make-- even if you're successful with milestones, it does wear you out. But that's what I tell them. I say, "You know, make sure that you take care of yourself a little bit, too." It's kinda like a analogy. What do you do for a pregnant woman who has a, who has a, a lupus? Lupus is terribly dangerous for the fetus and for the mom. Though the worst thing you do to-- for the baby is not take care of the mom. Take care of mom, [00:12:44] Lindsey Dinneen: Mm-hmm. [00:12:45] Andrew Holman: then get the baby delivered. So, you know, everybody's talking about the baby, but take care of mom. That's the most important thing you do for that baby. So that's kinda what I would say. [00:12:54] Lindsey Dinneen: Yeah. Yeah, that's great. I appreciate that. Yeah, that, that makes a lot of sense too. We've been talking, actually it's been a, a bit of a theme too lately in some of the conversations that I've been having with folks, especially leaders, to talk about that identity component and, and be aware that your job isn't the only thing that defines you or needs to. There's a lot more to your life. There's a lot more to who you are. And so also, you know, our identities change over time and how you refer to yourself and th- those are, those are good things. That's growth, that's movement. So, being comfortable with who you are outside of your career. Yeah. [00:13:33] Andrew Holman: The other thing too is, you know, people used to joke 20 years ago that participation mem- medals were like a farce and what. That's the l- that's the last thing I would say to anybody. Give yourself a pat on the back for going out there trying to attack the castle, you know. Give yourself some credit there because a lot of people just wouldn't do it. My middle daughter was a hundred-meter hurdler at Boise State. She's a Division I athlete. There's a lot of sprinters out there that don't wanna get anywhere near that hurdle 'cause it really hurts when you hit it, right? And so half of that was not-- was being brave. So be brave, be brave, you know. My other daughter was a Division I athlete at Rice. She was a h- she was a volleyball player. Yeah. So, yeah. So I, I, I, I watch other people, see how they persevere and, you know, okay, gotta pick yourself up. Gotta go. Gotta get up this morning. Gotta go. [00:14:23] Lindsey Dinneen: That's right. That-- Yeah. [00:14:25] Andrew Holman: Then remember, people are depending on you, not just your investors. I take that so seriously. But the s- the people who have decided that they're gonna hook their wagon to you. [00:14:34] Lindsey Dinneen: Yeah. [00:14:35] Andrew Holman: You know, that's a lot of responsibility. [00:14:37] Lindsey Dinneen: It is. Yeah. [00:14:38] Andrew Holman: Give yourself a little credit that you're stepping up. [00:14:41] Lindsey Dinneen: Yes. Great advice. Yeah. Okay, so all right. So let's talk about your company now. So now you're an entrepreneur, in addition to obviously the rest of who, what makes you, you. But and I know that you're also a clinical professor, and I would love to hear about both of those things if you don't mind sharing. [00:14:59] Andrew Holman: Yeah, sure. So, technically I'm an associate clinical professor at the University of Washington. A, a lot of private docs do, and they participate in helping teach the y-young residents and fellows and so forth. So it's a joy to me. I, I think my job is a job of teaching. I'm constantly talk... I'm not-- I don't see patients anymore, although I do maintain my license in malpractice 'cause I get, I get contacted for the fibromyalgia work I did. So it's, my email's on the papers, right? So I, I don't wanna let that go. People need help. But basically, we're constantly teaching patients, you know. Now, we're listening, hopefully do better and better at that, but then I have to make a case. You know, I'd, the-- I'd like you to try this or that. Why do I wanna do that and so forth. We're constantly, you know... We don't-- It, it sounds too trite to call it selling something. We're not doing that. We're in there with you. We're collaborating. But I have to be, I have to have a reason and be persuasive and all that, so that, that academic teaching part's kind of fun. Now, sometimes I go into the lion's den. I will tell you, it's a little nerve-wracking to give rheumatology grand rounds at Harvard. Yeah, yeah, okay. You know, and the University of Washington, they're a little friendlier. It's my hometown. But Guy's Hospital in London and the Hospital for Special Surgeries, I... My first rheumatology grand rounds came at the HSS in 2009. I get there, I completely bomb. All these famous people are in the front row. I'm... They're, they're just not buying any of this thing we call immunoautonomics and how stress affects the immune system. I'm quoting the NIH. I'm doing everything I... I know how to do it, right? Pathology slides, I'm there. Then I find out the way they pick the speakers is the fellows get to find something interesting, and they pick the speakers, not the not the high mucky-mucks. So the only reason I was there is because the fellows, the young folks, thought, "This is an interesting topic. We'd like to hear more." And it turns out they were 15 years ahead of the rest of the world, because this is the most fascinating topic of how the immune system affects the autonomic nervous system affects the immune system, so it inflames it. [00:17:03] Lindsey Dinneen: Yeah. Oh my gosh. Actually, that is one thing I wanted to talk about, 'cause I, I noticed on your LinkedIn profile there was, you know, a reference to how much stress affects cardiovascular health maybe particularly chronic stress. And I would just love to hear more about that and, and maybe some ways... I know there's like, y- of course you always get your standard, "Here are some things that you could do to lower your stress." But, but from your perspective as a physician who's studied this, I'd love to hear more from you about, okay, how does this affect health, especially cardiovascular health, and then really what are some practical things that we can do? [00:17:39] Andrew Holman: Yeah, let me see what I can do. Now I wish I could fast-forward because we will have some magnificent things in the next five to 10 years based on what's being discovered now. But the bottom line is, stress and pain are awful things, but they have a purpose in the near term. So pain is good because it'll keep you from putting your hand back in the fire, right? Just don't do that again. But chronic pain is terrible and not productive. Stress is the same thing. You wanna get away from the lion. You, you, you need to perform. If your child needs you, whatever, you, you need to perform on it instant. But chronic stress is not productive. The problem with the stress response is it's controlled in the brain by the autonomic nervous system, which is called the ANS, and it's divided into two components, the sympathetic fight or flight, which we all know what that feels like. You know, ooh, scary. And the other is the parasympathetic, which is getting more talk now, which is the opposite, which is related to rest, restorative, sleep, recovery, growth hormone, all these things. And both of these systems are on simultaneously all the time, but they jockey for predominance depending on what the demands are around you, right? So turns out the sympathetic part has a significant negative impact on cardiovascular health, as you might expect, right? If you're driving your car at five thousand RPMs-- now, nobody has a stick shift anymore-- but if you're driving at five thousand RPMs, you're gonna wear down your engine, even if you go at the same speed as someone who has a two thousand RPMs, right? It, it's, it's what's going on inside the hood there is really important. So stress responses chronically do have measurable, tangible, well-published effects on cardiovascular mortality in long prospective studies. So if we had a magic something, we would do something to lower that epinephrine adrenaline response. Unless, of course, you're in the military, where someone's-- you need every heightened, m-- you know, response that you can get to survive. But for the rest of us, it's better that that system does not ramp up and activate. And we all have a different propensity to how powerful it is and how much it turns on, and also how poorly it turns off. So the stress response, we think of it like epinephrine, adrenaline. That's the easiest way to do it. So what you'd wanna do is to make sure this magnificent part of your brain that is your-- does all your housekeeping functions, this autonomic nervous system, the command and control center that you just wanna work, you don't wanna think about it, is not on a turbocharged, right? And there are people I take care of that they were just born that way. A lot of them, by the way. So things like all the wellness opportunities you can think of are, are targeted just to simply calm the autonomic nervous system. Tai chi, meditation, diet, exercise, all these things have been around for thousands of years because of that. That's what they do. And the practitioners will share that with you. I mean, the there are monks that can lower their heart rate, you know, to like, you know, what would seem lethal to the rest of us, right? That's the parasympathetic drive that lowers heart rate, lowers blood pressure. So those wellness opportunities are real. It will be important that you can manage whether the-- what you're doing is working or not. [00:21:04] Lindsey Dinneen: Mm-hmm. [00:21:04] Andrew Holman: Right? And that's where my company comes in. But the other is things like obstructive sleep apnea. You might think heavy guys... See, someone's gonna send me for a sleep study for sure, but they're not gonna send you. Big mistake, because it turns out that fifty-three percent of Japanese women with rheumatoid arthritis have unexpected obstructive sleep apnea. Oops. And, and we were just taught that we wouldn't even check those people. Well, turns out sleep apnea untreated is a major cardiovascular risk factor equal to cigarette smoking, according to the Sleep Heart Health Study in 2004. That's a big deal. And also, we learned in rheumatoid arthritis, getting back to my work, world, that patients with rheumatoid arthritis don't die from joint disease, they die from premature heart disease. They can also get cancers. So why is that? Well, there's been a lot of effort to try to figure that out in the last twenty-five years, and their risk factors for cardiovascular disease are not explained by the Framingham risk factor of hypertension, cholesterol, smoking, and all the things we, we look, see. But nobody looked at sleep apnea. [00:22:15] Lindsey Dinneen: Mm-hmm. [00:22:17] Andrew Holman: The other reason it's so relevant, though, is sleep apnea is a potent sympathetic arousal. It, it-- You struggle to breathe, right? You kind of obstruct. And what part of your brain tells you to breathe? Your autonomic nervous system. Breathe, right? And it stimulates this adrenaline response over and over and over, and it pounds your heart over the years, and it can lead to sudden death and arrhythmias. So there's a, there's a link there. Never miss sleep apnea. The other one is we found in our office and published about restless leg syndrome. You know, people tap their toes in the airport or they kick the covers around at night. It's pretty benign for most people, but it looks like it very well might be a sympathetic arousal, and there may be relevance there. The therapies for that may have relevance to what we're talking about. Again, very off-label. We're not talking about FDA-approved here. But it-- You ask what can you do? The other one that's coming is vagus nerve stimulation. That is FDA-approved now for rheumatoid arthritis, and they're going to other opportunities to, again, to, to increase the parasympathetic and to lower the sympathetic, right? So that background activity doesn't harm you. The autonomic nervous system may be the primary reason that two patients respond differently to the same treatment. What you bring to the table. It's no different than if I have two people coming to me for a back problem. One is five foot three and one is seven foot three. The way their spine is designed makes it a whole lot harder to treat the seven-foot back, right? I'm not surprising anybody here. So there are things that the patients can bring to the table that matter. Here's the irony. Ninety-seven percent of patients with rheumatoid arthritis in a survey in England said that stress affected their disease activity. It's no surprise to them. And sixty-five percent said they thought it predated getting the disease, that it actually contributed to getting it in the first place. And now there's evidence to suggest that may be true. [00:24:17] Lindsey Dinneen: Oh, boy. [00:24:19] Andrew Holman: So we can't miss sleep apnea just out there. We can't miss restless leg. We can't miss Ehlers-Danlos type three hypermobility type where people can... you can't see me here, but my fingers can bend backwards. But it's, it basically it's very, very common, and those people tend to have increased sympathetic activity naturally. [00:24:39] Lindsey Dinneen: Fascinating. [00:24:39] Andrew Holman: So yeah, so we're, we're waking up a little bit to some very important features here of individuals that may help us do better with the diseases they also come in. [00:24:50] Lindsey Dinneen: Yeah. Wow. [00:24:52] Andrew Holman: Sorry, long answer. Sorry, but there's a lot. [00:24:54] Lindsey Dinneen: No, that's great. I appreciate it, and yeah, well, then there you go. Managing stress is critical to, to your health. It's not just a nice to have, like yeah, yeah, kind of thing. Okay. Whew. [00:25:07] Andrew Holman: Good learning. [00:25:08] Lindsey Dinneen: Okay, awesome. Yeah, so, I'm curious... Okay, so, so again, I like, I like looking at guests' LinkedIn profiles and, and learning more about, you know, what makes you tick outside of your career as well, and I noticed some very fun things that you have listed. So we've got creative writing, horsemanship, golf, and vintage passenger rail cars. I feel like this warrants... [00:25:33] Andrew Holman: Yeah, it's called... Yeah, the American Association of Private Railcar Owners. Yeah. I get ribbed a lot for that, but they're a great bunch. There are about --I don't know if I know all the numbers now, but about 75 to 80 vintage cars from the '20s, '30s, '40s, '50s, who tag on the back of Amtrak, and Amtrak drags them around, and you can actually go rent them, stay in them, whatever. And they have a a annual meeting where they just get on a private train, and they go on tracks that you wouldn't go on naturally, like private rails in the, you know, middle of nowhere. So that's what they like to do. And it's just a lot of fun, especially the dome cars. [00:26:12] Lindsey Dinneen: Okay. That's so cool. [00:26:14] Andrew Holman: I've been a handful of times. I've got a lot of friends there. I don't own a car, but boy, I'd sure like to have one. [00:26:19] Lindsey Dinneen: Yeah. Okay. That is so cool. And then how about horsemanship? How did you... Have you been riding horses your whole life, or how did that come about? [00:26:29] Andrew Holman: So I went to a high school called Thatcher School in Ojai, California, where there are 50 in a class, and there was a requirement, this is over 100 years old, this school, that you had to have a horse. And they would say s- that something about the "outside of a horse is good for the inside of a boy," right? I was the last all-male class in 1977. Now young women get to go there too. It's of note that I have 15 people from Thatcher investing as family and friends in, Inmedix. So, th-they that, that's pretty special. But it's a boarding school. I was there for four years. My dad had gone there, so I'd heard of it. But I got a tremendous education. Th-there aren't a lot of prep schools on the West Coast, but there are some. And, and that's where I learned how to ride a horse like riding a bicycle. My sister is a thoroughbred horse trainer for 40 years. She's retired. She had three or four or five horses, a har-- not the fancy kind of stuff at the Derby. But they, you know, get up at 4:00 a.m. and ride, you know, that kind of... Tough life, but she loved horses. So yeah, I, I'm as, I'm more comfortable on a horse than I am around anything, probably. [00:27:34] Lindsey Dinneen: That's so cool. Okay. Well, this has been really fun to, to get to hear your incredible life story so far, and I'm excited to see where the company continues to advance medical technology. So, you know, I really appreciate everything you're doing. But I do want to ask, is there a moment that stands out to you along your career path so far where you just thought, "Wow, I am in the right industry at the right time"? [00:28:02] Andrew Holman: Yeah, I'd, I'd say there probably was. When we unblinded the prospective double-blind study that we did looking at this five-minute next generation heart rate variability, this HRV we got through the FDA last year. When we unblinded the study, and although that's not part of the FDA clearance, it was a very important moment for me because it showed that it predicted a year in advance who would respond to treatment of rheumatoid arthritis with ninety percent sensitivity, ninety-five percent specificity. So I wanna emphasize that is not what it's cleared for. It's cleared as an HRV tool that doctors can use at their discretion. But that study is what you asked me to answer. And when you unlock a study and you see the results, two things happen. One is we were happy that I was on the right track. That was nice. You know, positive study. Your hypothesis is valid. But it completely changed the view of immunology, [00:28:58] Lindsey Dinneen: Hmm. [00:28:59] Andrew Holman: Because we would have a test now that could measure the autonomic nervous system with exquisite precision. Nobody cared except me. About 10 years ago, we were waiting for better biologics, the things on TV, right? They asked, "Ask your doctor if it's good for you." Nobody realizes that they work about twenty-five percent of the time in terms of disease control. That's a big gap, but it looks like it's the brain that monitors inflammation. The inflammation the immune system is not firewalled against everything. The brain c-controls it, and it's not the endocrine so much with cortisol, it's the autonomic that works in milliseconds that, that epinephrine response. So that's a... You know, you're pretty nervous when you un-- when you-- someone tells you, "Okay, here is the results." [00:29:48] Lindsey Dinneen: Yeah. Wow. [00:29:50] Andrew Holman: And, and, and that was it. And then it turned out in 2015, the other moment was when I was going through the airport at Seattle and I saw the cover of of Scientific American, Bioelectric Medicine, Setpoint Medical's vagus nerve stimulation, hacking the the vagus nerve to fix the autonomic nervous system to reduce the burden of rheumatoid arthritis. I go, "Okay, now it's time." We had the patent on it. Okay. Ten years forward, we're where we are now. We're launching in June, and we have a software juggernaut here and a literally a vital sign. So, th-the doctors decide what to do with this, but we've put it in their hands, and it's paid for by insurance. So yeah. [00:30:34] Lindsey Dinneen: Amazing. Well, that's, that's so cool. Congratulations on that. That's fantastic. Okay, so to pivot the conversation a little bit just for fun, [00:30:43] Andrew Holman: Hmm? [00:30:43] Lindsey Dinneen: imagine that you were to be offered a million dollars to teach a master class on anything you want. What would you choose to teach? [00:30:53] Andrew Holman: Well, I, I learned that you've all had professors that didn't probably know as much as they should about a subject, but they thought it was just fun. I would probably stick with what I know. So I would do a master class on fibromyalgia because you can actually treat it. And there's published data, but it's very-- it's not widely known. We will be using Inmedix and autonomic testing to do research to validate and get that problem finally solved and put to bed. And then the other is this thing called immunoautonomics. It, the term-- I made up the term 15 years ago. It's in the medical literature. So that's what I would teach. Teach what I know. [00:31:27] Lindsey Dinneen: I love that. Okay, excellent. And how do you wish to be remembered after you leave this world? [00:31:34] Andrew Holman: Well, I, you know, it all come... I define myself by what the patients, how they do and what they say. It's not about five stars and all that, you know, you know, there's plenty of those. But it's, it's... I made a, a commitment if somebody says anything about me, I made a commitment when I was a rheumatologist with all these mostly young women upset, that I would never leave the room with them crying. Didn't matter how far behind I was, didn't matter. We went through a lot of Kleenex. There's a l- it's devastating to get these diseases when you're a young woman. And they can put that on my tombstone, not to dismiss people. We had a saying in the office, "It's gotta be something." You know? It's, it's always something. Drives me crazy when doctors will say, "Oh, that's nothing." Well, well, first of all, we know it's not nothing. It, it is always something, and there's something that defines your success, and there has to be things that define your failure. So let's figure out what the something is, but let's not argue that there's nothing there. So let's not dismiss people who are frightened and worried, and maybe they don't tell the story as clearly as we'd hope. But you know what? It's not, it's not their fault. They're in distress. It's amazing what people are like after you help them with their chronic pain. [00:32:45] Lindsey Dinneen: Yeah. Yeah. That is really cool and makes so much sense. Yeah. Thank you. Okay, and then final question: what is one thing that makes you smile every time you see or think about it? [00:32:59] Andrew Holman: It's making me smile right now. When I talk to the young fellows that are in their training and they're finishing up, so they've done three years or four years of medicine, three years of internal medicine after that, and then they do three or two, three, four years of rheumatology, and then they're gonna go out, I tell them how jealous I am of what they're gonna see. The, the last, the last 40 years we had these young men mostly coming in with terrible weight loss and immune systems, falling apart, and these strange tumors, and they're dying of, of infections like yeast and candida that, you know, everybody did fine with, and it was HIV, right? It had to be figured out. Now HIV is a chronic disease. It's like diabetes. We had so many people die in the '80s. Hepatitis C was... You'd have liver enzymes up, and it wasn't hepatitis A 'cause we could test for that, and it wasn't hepatitis B 'cause we could test for that. So we just called it non-A, non-B. Literally, that's what we called it. And then that got to be called hepatitis C, right? 'Cause it was too embarrassing to call it n- what it wasn't. And now hepatitis C is curable with antiviral agents in, like, three weeks. I mean... And then the biologics showed up. They're not perfect, but they were a big step. And then this immunoautonomics and, and understanding how pain and sleep and the autonomic nervous system work. I'm just really jealous of what those young clinicians are gonna get to see. [00:34:27] Lindsey Dinneen: Yeah. Yeah, that's really... Yeah, I can see why. But it sounds like you are, you know, keeping, keeping your what, what would they say? Like, toe in the water or something so that you're able to, to watch some of this as well and be a part of that next [00:34:40] Andrew Holman: I feel like I'm a ne- I feel like I'm neck deep and I'm just hoping I don't go down any lower. [00:34:47] Lindsey Dinneen: Fair enough. [00:34:48] Andrew Holman: 'Cause I have to find a way to pay for it. [00:34:50] Lindsey Dinneen: Oh, yeah, yeah, yeah. The details, you know. Yeah, yeah. [00:34:53] Andrew Holman: You got those details, yeah. [00:34:54] Lindsey Dinneen: Yeah. Oh my gosh. Well, this has been an incredible conversation. I really appreciate your time today and sharing your insights and, and stories and, yeah, I'm so excited to see the future of medicine, and I appreciate perspectives of, like yours, where you just, you share a lot of hope and optimism, and you're actively working to change lives for a better world. So, thank you. [00:35:16] Andrew Holman: Yeah, I, I irritate a lot of people with that optimism, but I'm sorry, it's just there. I can't fix it. [00:35:22] Lindsey Dinneen: Brilliant. Well, I love it. It makes my heart happy, so thank you so much again, and I hope you have the best rest of your day. [00:35:31] Andrew Holman: Thank you so much. Thanks for having me. [00:35:32] Lindsey Dinneen: Of course. [00:35:34] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

This summer, join host David Mandell as he revisits and highlights episodes from Season 5 of The Wealth Planning for the Modern Physician podcast, in our 2026 Summer Rewind Series. "I genuinely believe there is a lot of information to gain from all of our episodes deliver, but for the summer, I've handpicked a few that offer intriguing ideas and a unique perspective for physicians in 2025," says David. "I hope you enjoy this Season encore series. Have a great summer!" Episode 5.18 | Originally Released: May 14, 2025 In this episode of the Wealth Planning for the Modern Physician podcast, host David Mandell sits down with two highly respected medical leaders—Dr. Mark Figgie, Chief Emeritus of the Surgical Arthritis Service at the Hospital for Special Surgery (HSS), and Dr. Joel Press, Physiatrist-in-Chief at HSS—to explore their personal and professional journeys in medicine. Dr. Press shares how his diverse early experiences led him to physiatry, while Dr. Figgie recounts his balance between science, business, and a lifelong pursuit of education, including earning an MBA during his fellowship. The conversation shifts into a discussion of mentorship at the Hospital for Special Surgery, where both physicians have played key roles in developing a cross-disciplinary mentorship model to support younger doctors. Their focus extends beyond clinical guidance to include career development, personal financial planning, and wellness—areas often overlooked in traditional medical training. This approach fosters institutional collaboration and a stronger culture at HSS. Finally, the episode dives into physicians' relationships with industry. Dr. Figgie offers candid advice on contracts, intellectual property rights, and ethical considerations when working with device manufacturers. He emphasizes the importance of legal review and staying true to what benefits patients. Dr. Press adds insight into personal financial trust, suggesting that doctors build a "board of directors" for trusted guidance. The episode closes with a preview of future initiatives aimed at supporting physicians earlier in their careers through financial education and mentorship. Learn more by visiting the original episode page. Learn more, including additional show notes, links, and detailed key takeaways, by visiting visiting the original episode page. Check out other episodes from our 6 seasons by visiting, physicianswealthpodcast.com. Click here to get your FREE copy of our latest book, Wealth Strategies for Today's Physician!

In this episode of HSS Presents, radiologist Dr. Harry G. Greditzer IV speaks with Dr. Andrew D. Pearle, Chief Emeritus of the Sports Medicine Institute at HSS, about the evolution of computer-assisted surgery and the emerging role of digital twins in orthopedics. Dr. Pearle explains how patient-specific MRI models, computational biomechanics, and additional data inputs may help clinicians assess ACL-injury risk, simulate surgical approaches, and personalize treatment planning. The conversation highlights neuromuscular training—a combination of strength, agility, plyometric, and landing-stabilization exercises—as an important strategy for reducing injuries among young athletes. Looking ahead, they also discuss how digital twins could support more individualized prevention, informed decision-making, and treatments designed around each patient's anatomy, movement patterns, and activity goals.

On this episode of Talking Guitars on Johnny Beane TV, we take a look at Charvel's brand-new Pro Plus Dinky DK24 models—four metal-focused guitars loaded with serious firepower, including Seymour Duncan Nazgul pickups, Floyd Rose tremolos, stainless-steel frets, and killer new finishes like Zombie Fade. Charvel has expanded the Pro Plus Dinky DK24 lineup with four new models designed for speed, precision, and heavy music. While these guitars are built for shredders, the pickup and hardware combinations make them especially interesting for modern metal players.

In this episode of HSS Presents, Dr. Scott Rodeo, Director of the Center for Regenerative Medicine at HSS, talks with sports medicine surgeon Dr. Yianni Apostolakos about the massive public interest and clinical realities surrounding Body Protection Compound 157 (BPC-157). Prompted by a widely read systematic review, the experts contrast promising preclinical animal data with the current lack of robust, human clinical trials. They discuss the shifting regulatory landscape—including recent FDA updates on compounding restrictions—and explain why these substances remain banned by WADA and major sports leagues. This conversation provides evidence for clinicians looking to ethically counsel both elite and recreational athletes on the use of these substances. Read the HSS Journal systematic review: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.

Ich spreche darüber, warum ein neuer BambuLab oder der nächste FDM-Drucker selten der entscheidende Schritt für mehr Produktivität ist. Du erfährst, woran du erkennst, dass dein 3D-Druck bereits bereit für den nächsten Technologiesprung ist und welche Rolle Pulverbettverfahren dabei spielen. Eine Folge für alle, die additive Fertigung nicht nur anwenden, sondern wirtschaftlich skalieren möchten.

Heart failure remains one of the leading causes of hospitalization among older adults worldwide. During episodes of acute decompensated heart failure (ADHF), excess fluid builds up in the lungs and body, making breathing difficult and increasing the risk of serious complications. Although intravenous loop diuretics such as furosemide are the standard treatment for relieving congestion, many patients continue to experience persistent inflammation, ongoing cardiac remodeling, and worsening heart function despite therapy. A research paper published in Volume 18 of Aging titled “Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF),” investigated whether combining intravenous furosemide with small volumes of hypertonic saline solution (HSS) could improve biological markers associated with heart failure compared with furosemide alone. Full blog post - https://aging-us.org/2026/08/hypertonic-saline-plus-furosemide-improves-heart-failure-biomarkers-in-randomized-trial/ DOI - https://doi.org/10.18632/aging.206364 Corresponding author - Antonino Tuttolomondo - bruno.tuttolomondo@unipa.it Abstract video - https://www.youtube.com/watch?v=EG65XlcDJ3U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206364 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, heart failure, acute decompensated heart failure, furosemide, hypertonic saline solution To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Fender Japan has done it again! The brand's new Limited Active Modern Series introduces some impressive innovations that many players have been asking for—and it raises one big question: Why aren't these features available on more U.S.-made Fenders? The new lineup includes two Stratocasters (SSS and HSS), a Telecaster, and a Modern Jazz Bass, all loaded with modern upgrades while staying true to classic Fender DNA. One of the biggest additions is the new Turbo Tone Boost. Activated with a push/push volume knob, it simulates the sound of a hotter single-coil pickup by electronically increasing the perceived winding effect—giving players a thicker, more powerful tone without changing pickups. Fender Japan also introduces a redesigned five-bolt neck heel, providing easier access to the upper frets while improving stability. The Stratocasters and Telecasters feature elegant body binding, a rare sight on production Fender Strats that gives these guitars a premium custom-shop vibe. Another standout feature is the new SILENCOIL system. Designed to eliminate hum while preserving the authentic tone and attack of traditional single-coils, it works independently from the pickups themselves—meaning players can swap pickups later and still keep the noiseless technology. Built with alder bodies, maple necks, premium fingerboards, and high-quality Japanese craftsmanship, the Active Modern Series blends vintage tone with modern performance. The guitars are available in finishes including Two-Color Sunburst, Feather Gray, Black, Sapphire Blue Transparent, and Vintage Natural. Unfortunately, there's one catch: the entire Active Modern Series is exclusive to Japan. Could these innovations eventually make their way to Fender's U.S. lineup? Many players are hoping so. What do you think? Would you buy one of these Fender Japan Active Modern guitars if they were available in the United States? #FenderJapan #FenderStratocaster #FenderTelecaster #ElectricGuitar

I discuss how the dooming never ends for those who can't see the bigger picture and the foundation that has been laid out for real accountability regarding treason and sedition in our elections and within our nation; I discuss recent examples of education fraud and how the AFT is involved in illegal voting and activism; HSS is losing 100 Billion in fraud; and a Flock camera website to track their locations. Substack:  https://theamericanclassroom.substack.com/p/the-2020-election-operation DeFlock:  https://maps.deflock.org/?lat=37.2652&lng=-96.9113&zoom=2.14   Book Websites: HERE and HERE. https://www.moneytreepublishing.com/shop PROMO CODE: “AEFM” for 10% OFF, or https://armreg.co.uk PROMO CODE: "americaneducationfm" for 15% off all books and products. (I receive no kickbacks).  https://www.thriftbooks.com/ Q posts book: https://drive.proton.me/urls/JJ78RV1QP8#yCO0wENuJQPH

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Mobility is foundational to life itself, yet musculoskeletal conditions quietly rob millions of people of the very movement that makes living worthwhile.Dr. Bryan Kelly, President and CEO of HSS, is leading a bold answer to that challenge. As the steward of the world's top-ranked orthopedic institution, now embarking on what he calls a Mobility Revolution, Dr. Kelly is expanding HSS far beyond its storied Manhattan campus.Through landmark partnerships with Deerfield Management, General Atlantic, Peloton, and beyond, HSS is building a global platform to unlock mobility for everybody, everywhere.Join us to discover how Dr. Kelly and the HSS team are leveraging cutting-edge innovation, data intelligence, and how his unwavering focus on the patient are redefining musculoskeletal health for generations to come. Let's go!Episode Highlights:HSS, founded in 1863, has grown into a world-leading musculoskeletal ecosystem spanning surgery, research, and rheumatology.Dr. Kelly, originally a music major, found his calling in orthopedics and built the nation's largest hip preservation service at HSS.HSS's bold new vision, "unlock mobility for every body, everywhere," targets the full care continuum from prevention to recovery.HSS is executing a four-concentric-circle growth strategy, physical expansion and a digital platform built on deep musculoskeletal data.Dr. Kelly and Deerfield Management launched a dedicated mobility venture fund targeting $400 million to $1 billion for musculoskeletal innovation.About our Guest:Dr. Bryan Kelly is the President & CEO, Surgeon-in-Chief Emeritus at HSS, which is the world leader in orthopedics, rheumatology and related disciplines. At the core of HSS is Hospital for Special Surgery, the largest academic medical center specialized in musculoskeletal health, founded in 1863. US News & World Report ranks HSS #1 in Orthopedics nationwide (past 16 consecutive years) and as a national leader in Rheumatology and a Best Hospital for Pediatric Orthopedics. HSS leadership spans patient care, research, education and innovation.Dr. Kelly and his more than 5,000 HSS colleagues are dedicated to the purpose of helping people get back to what they need and love to do, better than any other place in the world. To achieve this, he is focused also on advancing HSS as the best place for specialists in musculoskeletal health and all other team members to advance their careers.A world-renowned surgeon, scientist and educator specialized in sports medicine and hip preservation, Dr. Kelly arrived at HSS in 1996 with undergraduate and medical degrees from Brown University and Duke University. He completed his residency and two-year fellowship at HSS, followed by additional fellowships under the direction of Dr. Marc J. Philippon at University of Pittsburgh Medical Center and Dr. Herbert Resch at the Landeskliniken Hospital in Salzburg, Austria. He has spent much time collaborating with Professor Michael Leunig in Zurich, Switzerland and has established an exchange program for hip preservation trainees. Dr. Kelly completed his MBA at NYU Stern School of Business in 2019.Prior to assuming his role as President and CEO in 2023, Dr. Kelly served in several other leadership positions at HSS including Surgeon-in-Chief, Chief of the Sports Medicine Institute, and Chief of the Hip Preservation Service. He has a faculty appointment as Full Professor of Orthopedics at Weill Cornell Medical College and medical staff appointments at HSS and New York - Presbyterian Hospital. He has cared for several sports teams, serving as Head Team Physician for the New York Rangers, Assistant Team Physician for the New York Giants and Orthopedic Consultant for UFC.Over the past 20 years and with over 200 peer reviewed scientific publications, Dr. Kelly has played an instrumental role in the evolution and maturation of the field of hip preservation, which helps people of all ages with non-arthritic hip disorders to maintain mobility and stability. In 2010, he started the Hip Preservation Service at HSS, which is now the nation's largest with a 12-year record of fellowships.Dr. Kelly has a broad range of both clinical and basic science research interests including the development of a clinical outcomes registry; biomechanical studies evaluating conflict patterns in femoroacetabular impingement and techniques in labral refixation; development of synthetic scaffolds for labral reconstruction and cartilage injuries in the hip; and the development of novel surgical techniques for managing soft tissue injuries around the hip joint.More information about HSS can be found at HSS.edu.Links Supporting This Episode: HSS website: CLICK HEREDr. Bryan Kelly LinkedIn page: CLICK HEREHSS LinkedIn page: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE

In this episode of HSS Presents, residents Dr. Mark Megerian and Dr. Austin Kaidi host an insightful conversation with HSS orthopedic trauma surgeon Dr. Aleksey Dvorzhinskiy to explore the vital role of mentorship in surgical training. Dr. Dvorzhinskiy reflects on the ideological frameworks passed down by his own influential mentors, focusing on the core pillars of being morally incorruptible, pursuing technical excellence, and suppressing ego in the operating room. The panel dives into the nuances of surgical instruction, discussing how effective mentors distinguish between "tough love" and encouragement based on a resident's intrinsic motivation. Blending perspectives from a junior resident, a chief resident, and an attending, this episode offers a thoughtful roadmap on how to actively engage as a mentee and successfully transition into a surgical leader.

In this episode of HSS Presents, orthopedic resident Dr. Tyler Khilnani sits down with Dr. Samuel A. Taylor, a sports medicine orthopedic surgeon at HSS and associate team physician for the New York Giants. Drawing from his own background as a former Harvard varsity football player, Dr. Taylor pulls back the curtain on the intense, year-round responsibilities of caring for elite athletes. From navigating the high-stakes environment of the NFL Combine to managing evolving game-day injuries on the sidelines, he highlights the critical role of communication in a multidisciplinary sports medicine team. Ultimately, Dr. Taylor discusses the balancing act between clinical practice, resident education, and family life, offering invaluable advice for trainees aspiring to enter the field of team coverage.

In this episode of HSS Presents, orthopedic surgery resident Dr. Mark Megerian sits down with Dr. Mark Figgie, a hip and knee replacement surgeon who has spent four decades at HSS advising residents, fellows, and attendings as they transition to practice. Dr. Figgie shares practical guidance on evaluating a first job, from leveraging the HSS alumni network and vetting potential partners to reading the fine print on buy-in structures, non-compete clauses, and malpractice tail coverage. They also discuss how to negotiate for specific technology, approach salary conversations without alienating a prospective employer, and weigh private versus academic career paths.

Iedereen kent afwijzingsgevoeligheid. We willen allemaal ergens bij horen. Maar wat als die angst voor afwijzing je keuzes, grenzen, werkgeluk en zichtbaarheid gaat bepalen?In deze aflevering spreek ik met Saskia Klaaysen, HSP/HSS-coach, trainer, opleider en auteur van de bestseller Prikkels bijten niet!. We hebben het over rejection sensitivity: afwijzingsgevoeligheid die kan ontstaan wanneer je steeds opnieuw ervaart dat je afwijkt van de norm. Dat zie je vaak bij neurodivergente mensen, zoals HSP's, HSS'ers, mensen met ADHD, autisme, hoogbegaafdheid of dyslexie. Maar het kan bij iedereen ontstaan, bijvoorbeeld door opvoeding, trauma of het gevoel dat jouw manier van zijn “niet klopt”.Saskia legt uit hoe rejection sensitivity zich laat zien via sociale triggers (hoor ik erbij?) en prestatietriggers (doe ik het goed genoeg?). We bespreken waarom mensen gaan pleasen, perfectionistisch worden of zichzelf kleiner maken en wat dat doet met werkgeluk en met het benutten van neurodivergente talenten op de werkvloer.De oplossing is geen quick fix. Volgens Saskia gaat het om zelfacceptatie, zelfcompassie, oude coping doorbreken en stap voor stap meer zichtbaar worden. Luister mee als je wilt ontdekken hoe je uit de houdgreep van afwijzingsgevoeligheid kunt bewegen en meer ruimte maakt voor jezelf, je behoeften en je talenten.Volg Saskia op LinkedIn of Instagram.Bestel Saskia's boek ‘Prikkels bijten niet: https://anahatatraining.kennis.shop/pay/prikkelsnlMeer over de online masterclasses Rejection Sensitivity: Anahata Coaching & Training

BUFFALO, NY — April 7, 2026 — A new #research paper was #published in Volume 18 of Aging-US on March 26, 2026, titled “Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF).” Led by first author Mario Daidone from University Hospital, Policlinico, Paolo Giaccone, and the University of Palermo, with corresponding author Antonino Tuttolomondo from University Hospital, Policlinico, Paolo Giaccone, and University of Palermo, the randomized trial compared i.v. furosemide plus small-volume hypertonic saline solution (HSS) with i.v. furosemide alone in patients with acute decompensated heart failure due to reduced ejection fraction. The study enrolled 200 subjects, randomly assigning 107 to furosemide plus HSS and 93 to furosemide alone. The authors found that patients treated with i.v. furosemide plus HSS showed lower increases in inflammatory and remodeling biomarkers after saline load, including IL-6, hsTnT, sST2, galectin-3, and NT-proBNP, and the intervention was associated with reduced miR181b expression compared with furosemide alone. These findings suggest that adding small-volume hypertonic saline to loop diuretic therapy may influence both circulating biomarkers and miRNA-related epigenetic signatures in acute heart failure. “Nevertheless, the possible effects of the i.v. furosemide + HSS treatment on natriuretic and inflammatory markers of heart failure deserve further confirmation, whereas the effects of this type of treatment on epigenetic signatures of pathologic mechanisms involved in the left ventricular dysfunction involved in AHF pathogenesis seem to be still not studied.” The authors note that this was a randomized trial in a specific ADHF population, so additional studies will be needed to confirm the durability of the biomarker changes, define the optimal patient groups, and determine whether these molecular effects translate into improved clinical outcomes. Future work may also clarify how the saline strategy interacts with cardiac remodeling and miRNA regulation in larger and more diverse heart failure cohorts. DOI - https://doi.org/10.18632/aging.206364 Corresponding author - Antonino Tuttolomondo - bruno.tuttolomondo@unipa.it Abstract video - https://www.youtube.com/watch?v=EG65XlcDJ3U Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206364 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, heart failure, acute decompensated heart failure, furosemide, hypertonic saline solution To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Hrvatski predsjednik Milanović ne želi srbijanskog kolegu Vučića u Hrvatskoj, otkazao je regionalni summit Brdo-Brijuni. Premijer Plenković na korak je do još jedne saborske ruke, po svemu sudeći u većinu ulazi HSS. Za tradicionalnu uskrsnu prehranu četveročlanoj obitelji treba 164 eura.

Our guest this week is a Surfer, skater, snowboarder, and HSS alumni, turned 6-time Emmy nominee and 2-time Emmy Award-winning director. His work spans film, television, and global brand storytelling. He's collaborated with heavy hitters like FX, Netflix, Apple Music, as well as iconic brands including Porsche, Nike, Levi's, Microsoft, and Disney. His creative range even extends into music videos, working with legends like Tom Petty and cutting-edge artists like XG.He directed narrative pieces for the Olympic Channel's Game Breakers, and has shadow directed on major productions like The Politician and the Emmy nominated, Producers Guild Award winning series Shōgun. Now he's bringing that vision to his latest project, Lotus Point, a homage to 90's Surf and Skate culture, inspired by classics like North Shore, Point Break, Thrashin', Rad, Gleaming the Cube, The Goonies, and more. We're fired up to dive into his journey, his creative process, and what's next, we welcome to the show Mr. Joel Kazuo Knoernschild.

Cheesy and Fondue learn about non-dairy cheese. We talk about ancient fermented tofu. We find out about alternates to milk like rice, mealworms, seaweed and AI produced casein. And of course, we tell a very cheesy joke!Find us at www.justcheesy.com and everywhere you enjoy social media! https://linktr.ee/JustCheesy***Newsly is the sponsor of this episode! Go to https://newsly.me to download the free app and listen to articles, podcasts and digital radio! Get a FREE 1-Month Premium Subscription by using promo code CHEESY. Start listening today! *** Why is cheddar the most dangerous of all the cheeses? Because it is very sharp! Show Notes https://phys.org/news/2026-03-rice-based-cheese-possibility.htmlhttps://www.soyinfocenter.com/HSS/fermented%20_tofu1.phphttps://pubmed.ncbi.nlm.nih.gov/11322691/https://www.rimping.com/blog/7505/vegan-cheese-historyhttps://phys.org/news/2023-10-ancient-technology-plant-based-cheese.htmlhttps://modernfarmer.com/2023/08/the-future-of-cheese/https://www.dairyreporter.com/Article/2023/06/27/how-climax-foods-ai-produced-casein-could-spell-a-new-frontier-for-plant-based-cheese/https://vegnews.com/climax-foods-plant-based-caseinhttps://www.treelinecheese.comhttps://rebelcheese.com/collections/shop-all-products?srsltid=AfmBOopyG-R_OZUsMxtK7s_4WDmmGqGVQ57xR5Q2gsWTGRQBnCnv0A_C&page=2https://thevreamery.com/?srsltid=AfmBOooSzjZa-wBB6ytddJzacS9ISgLjFFzDFoYvRnqlVG-2mGDgCl7_

Send a textIs being inactive more dangerous than we think? In this clip from our episode “Why Exercise Beats Longevity Hacks”, CareTalk host John Driscoll speaks with Dr. Jordan Metzl, Author of The Athlete's Book of Home Remedies, about why movement may be the most powerful preventive medicine we have, even in the era of GLP-1s.Listen to the full episode here

We get a lot questions from our listeners each week and they're great questions,so rather than responding individually we thought we'd do these mini episodes where highlight some of the best questions and our responses. So, let's get started! Today's Ask The Sports Docs focuses on timing of ACL reconstruction surgery. Our patients, and their families, frequently ask… how long can I wait tohave the surgery? To answer that question, we're going to review an article, hot off the press in this month's issue of AJSM titled “Early ACL Reconstruction Mitigates the Development of Posttraumatic Osteoarthritis in a Murine ACL Rupture Model.” Dr. Julia Retzky and colleagues at HSS sought to answer the question:Does the timing of ACL reconstruction actually matter for long-term joint health?This is a timely paper because posttraumatic osteoarthritis or “PTOA” after ACL injury remains a massive unsolved problem. Even with modern reconstruction techniques, we're still seeing 23 to 60% rates of PTOA at 10 to 25 years post-op. Historically, the literature on timing is all over the place. Some studies suggest early ACLR may reduce PTOA risk, others show no difference. The problem isheterogeneity—different grafts, definitions of “early,” imaging versus radiographic OA, meniscal status, you name it.And that's where this paper is interesting. It strips away a lot of clinical confounders by using a controlled murine model (or mouse model) with a noninvasive closed ACL rupture, followed by either immediate reconstruction, delayed reconstruction, or no reconstruction. And importantly, this is the first murine study using a true intra-articular ACL reconstruction model, rather than extra-articular stabilization. So this mirrors what we do clinically, with a true anatomic ACL reconstruction.So, let's dive in...

Send us a textThe longevity boom is full of supplements, hacks, and expensive routines, but most of it ignores the simplest lever we already know works. If movement is the most studied “drug” for healthy aging, why are so many people still stuck on the sidelines?Dr. Jordan Metzl, Author of The Athlete's Book of Home Remedies joins CareTalk host John Driscoll, Chairman of UConn Health, to discuss why exercise is the most powerful prescription for healthspan, how motivation can be built through practical behavior change, and how strength and community can help prevent chronic disease over the long run.

In this episode of HSS Presents, physical therapist Snehal Patel sits down with Dr. Riley Williams, Chief of the Sports Medicine Institute at HSS, and Michael Chronert from DARI Motion to talk about the future of motion capture in patient care. They discuss how DARI's AI-driven tech is changing the game by offering a quick, markerless way to analyze movement without needing a full biomechanics lab. Dr. Williams explains how swapping manual exams for this kind of objective data—measuring things like limb symmetry and loading—leads to smarter "return to sport" decisions. It's a great look at how the field is moving from simple observation to high-tech precision to get athletes back in the game safely.

In this episode of HSS Presents, rheumatologist Dr. Caroline Siegel is joined by HSS colleagues Dr. Lisa Samaritano and Dr. Jane Salmon to discuss managing pregnancy for patients with autoimmune rheumatic diseases. They emphasize that most patients have successful pregnancies, but conditions like systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) carry greater risks, including preeclampsia and placental insufficiency. Successful outcomes rely on preconception planning, which includes achieving quiescent disease for about six months on pregnancy-compatible medications and screening for antibodies. Dr. Salmon also shares exciting clinical trial results using a TNF inhibitor to improve pregnancy outcomes in high-risk APS patients.

On this episode of DGTL Voices, Ed interviews Justin Oppenheimer, EVP of Hospital for Special Surgery (HSS). They discuss Justin's personal journey, including his athletic background, pivotal life lessons, and the importance of family values. Justin shares insights on his career at HSS, the evolution of leadership, and the impact of technology and AI in healthcare. The conversation emphasizes the significance of helping others and finding one's purpose in life.

Welcome to GamePlan with the Sports Docs. On each of these mini episodes, we chat about a new article or new surgical technique in the field of sports medicine. We'll give you our quick take on the most recent data and how this data will be impacting our practice.Today, we're talking about hamstring injuries in the NFL. And if your fantasy team is anything like my fantasy team, it currently looks like an infirmary. So, you'll probably want to listen in to this episode.Now, we've covered hamstring injuries in the NFL before.  Last year we did an entire Game Plan episode dedicated to this topic.  That is episode #52 if you want to check it out. Today, we are actually reviewing a new study just published this month in AJSM that focused on how player characteristics, injury severity and imaging findings can impact the amount of time missed as well as risk of recurrent injury. The article is titled “Correlation of Player and Imaging Characteristics with Severity and Missed Time in the National Football League Professional Athletes with Hamstring Strain Injury.” Molly Day, Scott Rodeo and team at HSS published this retrospective cross-sectional study that aimed to identify certain player characteristics, clinical examination findings and MRI  results that were associated with injury severity and missed playing time. As always, links to all of the papers that we discuss on this show can be found on our podcast website – www.thesportsdocspod.com

This week, we're diving into some major Peloton fitness news. Is Peloton really integrating ChatGPT into the platform? We discuss what that could mean for your workouts and the future of connected fitness. Plus, we break down the new Breathwrk feature, a sweet apparel discount for our Canadian friends, and a huge new perk for Club Peloton members.Unfortunately, it wasn't all good news. Peloton was hit by a recent AWS outage, and we'll fill you in on what that meant for your classes. The company is also trying to get an investor lawsuit tossed out. On the instructor front, we have an important health update from Selena Samuela and some exciting news about Jess King. We also finally reveal last week's mystery instructor apparel collaboration.We're also talking about major legal battles in the fitness wearable world as Whoop sues Polar and Suunto sues Garmin. What does this mean for the future of fitness trackers? All this, plus our TCO Top Five favorite fitness classes of the week.Peloton is exploring an integration with ChatGPT. What could this mean for the future of Peloton fitness?Peloton adds Breathwrk meditation content to its lineup.A new Club Peloton discount is available for the Canadian apparel site.Club Peloton members get a significant new perk.The recent AWS outage affected Peloton services.Peloton files a motion to dismiss a pending investor lawsuit.Instructor Selena Samuela shares her gestational diabetes diagnosis.Jess King is set to DJ for Diplo's run club.Last week's mystery instructor apparel collaboration is revealed.The latest Artist Series features the music of Jorja Smith.Wearable tech drama: Whoop is suing Polar.And in more legal news, Suunto is suing Garmin.Bodi announces a new partnership with Tony Horton & P9X.The TCO Top Five: We recap the community's favorite Peloton classes of the week.This Week at Peloton: A look at the upcoming schedule.TCO Radar: Classes we are excited to take.A look at Peloton's special Halloween fitness classes.Peloton partners with HSS for new injury prevention classes.Jess Sims hosts her first Run Club class.Peloton Birthdays: Happy Birthday to Matt Wilpers (10/24) and Emma Lovewell (10/25)!Join The Clip Out community!Subscribe to our newsletter and find all our links at theclipout.com.Leave us a review on Apple Podcasts or Spotify See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of HSS Presents, anesthesiologist Dr. Jeffrey Ciccone speaks with physiatrist and pain management specialist Dr. Faye Rim about preventing the transition from acute to chronic pain after surgery. They explore risk factors such as inflammation, central sensitization, opioid tolerance, and psychosocial influences, while highlighting the importance of proactive screening and multimodal pain strategies. Dr. Rim shares how HSS's transitional pain service identifies high-risk patients, coordinates perioperative care, and incorporates novel therapies—including ketamine infusions, nerve catheters, and new sodium channel blockers. The conversation emphasizes early intervention, individualized treatment, and system-level changes to improve recovery and reduce long-term disability.

In this episode of HSS Presents, rheumatologist Dr. Anne Bass is joined by Dr. Deanna Jannat-Khah of HSS and Dr. Michael Postow of Memorial Sloan Kettering to explore immune checkpoint inhibitor–induced arthritis. They discuss how life-saving immunotherapies for cancer can trigger inflammatory joint disease, the challenges of balancing tumor control with autoimmune toxicity, and the latest evidence on safe use of steroids and biologics. The panel also highlights ongoing research into mechanisms, phenotypes, and long-term outcomes, underscoring the importance of multidisciplinary care for cancer patients who develop musculoskeletal complications from immunotherapy.

In this episode, we're going to continue our discussion with Dr. Travis Matheney and focus on surgical treatment options for borderline hip dysplasia.Our conversation picks back up with a review article published in the December 2024 issue of Current Reviews in Musculoskeletal Medicine titled “Borderline Hip Dysplasia - Best Treated with Hip Arthroscopy or Periacetabular Osteotomy?” Dr. Andrea Spiker and colleagues summarized the current research comparing isolated hip arthroscopy to periacetabular osteotomy for patients with borderline hip dysplasia.  They noted improved postoperative clinical outcome scores and low rates of conversion to total hip arthroplasty in both groups.  The authors concluded that successful clinical outcome seem to rely on treating underlying clinical pathology as well as appropriate surgical indications and surgical techniques.Then, from the April 2021 issue of OJSM, we review an article titled “Comparison Between Hip Arthroscopic Surgery and Periacetabular Osteotomy for the Treatment of Patients With Borderline Developmental Dysplasia of the Hip.” This systematic review authored by Dr. Marc Philippon and his team at the Steadman Clinic in Vail found that outcomes improved across all patient reported outcome measures whether patients were treated using arthroscopic surgery or PAO.  They noted that revision surgery was also common in both procedures. We finish up with an article from the September 2017 issue of AJSM titled “Early Functional Outcomes of Periacetabular Osteotomy After Failed Hip Arthroscopic Surgery for Symptomatic Acetabular Dysplasia.” Bryan Kelly and his team at HSS investigated the effect of prior arthroscopic hip surgery on clinical outcomes after periacetabular osteotomy or “PAO”. They found that patients who previously underwent hip arthroscopy had inferior functional outcomes at 6 months and 12 months after PAO compared to patients with no prior hip surgery. The authors note that both groups significantly improved post-op and there was no difference in complications or reoperation between the groups. 

Trump v Omar. HSS fraud was reported to the state more than two years ago and nothing was done about it. Everyone in the state is justified in wondering how high this fraud actually goes. Johnny Heidt with guitar news. Heard On The Show:Riding the Gold Line: Nearly empty buses the normFormer KSTP-TV anchor Stan Turner dies after battle with cancerWhat to know about the H-1B visa Trump has targeted with $100,000 fees, generating confusion, fearSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Illinois Governor JB Pritzker reacts to breaking news that Disney's ABC television network has capitulated to strong-arming by the Trump administration to remove Jimmy Kimmel from the air, and encourages Americans to not only push back on Disney, but to remain steadfast in standing up to Donald Trump's intimidation tactics. Former federal prosecutor Preet Bharara weighs in on the legal perspective, and Rep. Dan Goldman joins to discuss Donald Trump's power overreach.Jen Psaki reports on a Senate health committee hearing in which Republicans were trapped trying to maintain the Trump administration's anti-vaccine attitude in the face of well-informed testimony from former CDC officials, including Republican-confirmed former CDC Director Susan Monarez, pushed out by Trump's HSS secretary, Robert F. Kennedy Jr. Dr. Debra Houry, the CDC's former chief medical officer, who also testified at today's hearing, joins to discuss the lack of scientific rigor and transparency from Trump's new health officials. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of HSS Presents, rheumatologist Dr. Genna Braverman hosts a conversation with Dr. Arthur Yee and cardiologists Dr. Evelyn Horn and Dr. Irina Sobol on the interplay between the heart and rheumatic diseases. They discuss how conditions like sarcoidosis and scleroderma can affect the myocardium, valves, conduction system, and pulmonary vasculature—leading to heart failure, arrhythmias, and pulmonary hypertension. The panel highlights advances in imaging, from cardiac MRI to PET scans, and evolving treatments that combine immunosuppression, device therapy, and guideline-directed cardiac care. With insights into the new Cardio-Rheumatology Program at HSS and Weill Cornell, listeners will hear how collaboration between specialties is improving outcomes for patients with autoimmune diseases that affect the heart.

The Big Unlock · Digital Twins Could Be a Game-Changer for Scalable Healthcare Innovation – Podcast with Inderpal Kohli In this episode, Inderpal Kohli, Healthcare Executive Leader (Englewood Health, HSS, and Columbia University Medical Center), shares his vision for scalable digital health transformation. He outlines a proven framework focused on patient engagement, clinically integrated care, and remote patient monitoring—strategies that have already driven an 18–20% increase in online scheduling and improved outcomes in preventive care campaigns. Inderpal also reflects on how a chance project in biomedical informatics sparked his passion for digital transformation, leading to pioneering work in digital pathology, remote monitoring, and digital front door solutions. He explores the promise of ambient documentation in reducing clinician burden and enhancing satisfaction, and addresses the persistent challenge of integrating EHR systems with third-party tools—stressing the importance of seamless integration for meaningful impact. He also discusses the potential of digital twins as a game-changer, shares lessons on building agile, consumer-focused digital teams, and weighs in on how GenAI and agentic automation are poised to reshape care delivery. Take a listen.

Trump weighs in on Sydney Sweeney being a registered GOP and a new track from the AI Overlords. Plus, HSS gets shut down after fraud investigations, and Foes of the show go full racist. 

 The Big Unlock Podcast · AI If Done Right Can Rehumanize Healthcare – Podcast with Ashis Barad In this episode, Ashis Barad, Chief Digital Technology Officer at the Hospital for Special Surgery (HSS), discusses his journey in rehumanizing healthcare through digital health transformation. A practicing pediatric gastroenterologist, Ashis advocates for tech that genuinely solves problems, viewing himself as a “doctor first, technologist second.” Ashis stresses on Agentic AI and change management as pivotal elements in healthcare transformation. Healthcare is inherently workflow-centric, not a series of isolated moments. Barad explains Agentic AI as a workflow orchestrator designed to reduce administrative waste, enhance patient experience, and accelerate the adoption of best practices. Ashis outlines HSS's strategy to leverage its specialized focus to build a modern data lakehouse architecture and deploy AI-powered solutions through key partnerships. He envisions rehumanizing healthcare by automating backend processes, expanding clinician-patient time, and codifying best practices that can be scaled globally, especially in musculoskeletal care and movement. Take a listen.

Mike Welch tournament director for the 3M Open taking place next week. Get your tickets hereFeds execute search warrants connected to ‘massive scheme to defraud' a Minnesota housing programAlpha News was on location as a search warrant was being served at several locations related to a “massive scheme to defraud” Medicaid and Minnesota's Housing Stabilization Services (HSS) program.According to the search warrant, the fraud investigation involves HSS providers who billed for various services intended to provide stable housing for Minnesotans.The search warrant states, “The Program has proved to be extremely vulnerable to fraud.”The vulnerability stems from limited requirements for service providers and the vast services they can provide for Medicaid reimbursement.“Since Minnesota became the first state to offer Medicaid coverage for Housing Stabilization Services, dozens of new companies have been created and enrolled in the program. These companies, and the individuals who run them, have taken advantage of the housing crisis and the drug addiction crisis in Minnesota to prey on individuals who need help getting back on their feet as they recover from drug addiction,” the warrant says.“These companies and individuals do so by contacting Medicaid-eligible people in halfway houses and residential drug treatment facilities and offering to help them find stable housing. After registering these people to receive housing stabilization services, the companies fraudulently claim to provide dozens of Program service hours to their new ‘clients.' In reality, client after client has reported that they received little or no actual services or assistance from these companies. But the companies engaged in this scheme have received millions of dollars in Medicaid funds for housing stabilization services they did not actually provide,” it continues.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mike Welch tournament director for the 3M Open taking place next week. Get your tickets hereFeds execute search warrants connected to ‘massive scheme to defraud' a Minnesota housing programAlpha News was on location as a search warrant was being served at several locations related to a “massive scheme to defraud” Medicaid and Minnesota's Housing Stabilization Services (HSS) program.According to the search warrant, the fraud investigation involves HSS providers who billed for various services intended to provide stable housing for Minnesotans.The search warrant states, “The Program has proved to be extremely vulnerable to fraud.”The vulnerability stems from limited requirements for service providers and the vast services they can provide for Medicaid reimbursement.“Since Minnesota became the first state to offer Medicaid coverage for Housing Stabilization Services, dozens of new companies have been created and enrolled in the program. These companies, and the individuals who run them, have taken advantage of the housing crisis and the drug addiction crisis in Minnesota to prey on individuals who need help getting back on their feet as they recover from drug addiction,” the warrant says.“These companies and individuals do so by contacting Medicaid-eligible people in halfway houses and residential drug treatment facilities and offering to help them find stable housing. After registering these people to receive housing stabilization services, the companies fraudulently claim to provide dozens of Program service hours to their new ‘clients.' In reality, client after client has reported that they received little or no actual services or assistance from these companies. But the companies engaged in this scheme have received millions of dollars in Medicaid funds for housing stabilization services they did not actually provide,” it continues.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of HSS Presents, Dr. Peter Sculco, MD, sits down with Dr. Amar S. Ranawat, MD, to talk about the future of robotics in revision joint surgery. With decades of experience in complex hip and knee revisions, Dr. Ranawat shares why he continues to rely on manual techniques and outlines the key principles behind successful outcomes. They discuss the current limitations of robotic systems in revision cases, the importance of restoring the joint line, and the critical role of expert surgical teams. The episode also looks ahead to emerging technologies, from AI-driven planning to smarter robotic tools, that could reshape how complex joint reconstructions are performed. To learn more about The Stavros Niarchos Complex Joint Reconstruction Center at HSS, visit our HSS webpage and our X account.

In this final episode of Season 5, host David Mandell recaps the season's key themes and previews the upcoming Summer Rewind series, which will highlight standout episodes from Seasons 3 and 4. The podcast will continue on a biweekly schedule over the summer, with new introductions to previously released episodes, allowing listeners to revisit valuable content over the Summer. David reviews each of the 18 episodes of Season 5, including a quick recap and highlights. The goal of this episode is to help listeners catch up on missed episodes or revisit important insights they may have forgotten. He invites feedback and topic suggestions for future episodes as the podcast continues to grow its audience. EPISODE SNAPSHOTS: 5.1 & 5.2 – Dr. Jay Foley: After a life-altering snowboarding accident, Dr. Foley transitioned from surgery to medico-legal consulting, highlighting the importance of disability insurance and leveraging a medical license in new ways. 5.3 – Andy Taylor: Explored how election cycles influence market behavior and how physicians can remain calm and strategic with their portfolios. 5.4 – Nolan Bradbury, CPA: Covered KPIs, practice delegation, legal/tax structure for side hustles, and exit planning from a CPA's perspective. 5.5 – Dr. Ben Ostrander: Applied hospitality industry lessons to healthcare to enhance patient experience, employee satisfaction, and operational efficiency. 5.6 – Jessica Jones, Consultant: Shared insights on aligning practice models with physician passion, wellness trends, and diversification within practices—especially cash-based models. 5.7 & 5.8 – Dr. Sue Keller: An unflinching look at financial mismanagement, the emotional toll of bankruptcy, and finding meaning in a reinvented career after decades in dentistry. 5.9 – Dr. Jay Zigmont: Introduced “child-free wealth” as a growing financial niche, challenging traditional planning assumptions and offering guidance tailored to child-free individuals. 5.10 – Dr. Jude Pierre (Pt. 1): Talked about geographic and specialty shifts, mentorship, and the creation of a physician coaching practice to fight burnout and debt. 5.11 – Carole Foos & Greg Heimkreiter, CPAs: Discussed looming tax law expirations, industry-wide challenges in accounting services, and what physicians should know about finding quality tax advisors. 5.12 – Kristy LaGourgue & Rachel Varga: Focused on brand building and marketing strategy for all doctors, not just those in aesthetics—emphasizing the importance of digital presence and patient communication. 5.13 – Dr. Pat St. Pierre: Reflected on a military-to-medicine career, financial planning, industry involvement, and proactive retirement through wine education to avoid post-retirement difficulty. 5.14 – Attorneys Byrd & Adatto: Covered major legal trends including compounding pharmacy scrutiny, the evolving legal landscape around non-competes, and internal practice exits. 5.15 – Dr. Jude Pierre (Pt. 2): Discussed optimizing workflow through scribes, practice innovation via Medicare Advantage, and financial/lifestyle balance to avoid physician burnout. 5.16 & 5.17 – Cory Kleinschmidt: Provided a comprehensive look at locum tenens work for physicians—ideal for both early-career flexibility and late-career freedom—including licensing, contract tips, what to look for in an agency, forming LLCs for tax purpose and more. 5.18 – Drs. Mark Figgie & Joel Press: Shared a mentorship model from HSS that helps young physicians with career planning, finances, wellness, and leadership development. 5.19 – Bob Goettling: Introduced ESOPs (Employee Stock Ownership Plans) as an innovative, tax-efficient practice exit strategy increasingly relevant in the medical space.     Learn more, including additional show notes, links, and detailed key takeaways, by visiting physicianswealthpodcast.com. Click here to get your FREE copy of our latest book, Wealth Strategies for Today's Physician!

Today's episode is kind of an Overtime / Ask The Sports Docs crossover. One of the PTs that Ashley works closely with asked her why some patients do well after ACL surgery and some don't fare as well, despite the surgery being identical in terms of technique, graft choice, post-op protocol etc. An article was just published in AJSM this month looking at this, specifically investigating factors that impact outcomes after ACL reconstruction. The article that we are reviewing today is titled “Primary Anterior Cruciate Ligament Reconstruction in Level 1 Athletes: Factors Associated With Return to Play, Reinjury, and Knee Function at 5 Years of Follow-up.” This level 2 cohort study aimed to analyze the outcomes of primary ACLR in level 1 athletes and identify preop and intraop factors associated with RTP, ipsilateral ACL reinjury, contralateral ACL injury, and IKDC score at 5 years post-op.** We have also been chatting about this episode offline and discussed an article that was recently published looking at preoperative grit scores and postoperative range of motion after ACL reconstruction. Grit score is another objective measurement that we can obtain preoperatively and perhaps use to guide intervention during post-op recovery. We actually did an Overtime episode looking at the impact of grit scores on post-op outcomes after ACL reconstruction. That is episode #53 if you want to check it out! But today's second article is titled “Higher Grit Scores Are Associated With Earlier Increases in Knee Flexion Following Anterior Cruciate Ligament Reconstruction With Meniscus Repair in Pediatric Patients.” It was published in the April 2023 issue of the Journal of Pediatrics. Pete Fabricant and his team at HSS found that patients with grit scores below the 50th percentile undergoing ACLR + meniscus repair have 5 degrees less total ROM at 3 months compared with those with high grit scores. Though 5 degrees might not seem like a lot, quicker motion recovery in patients with high grit may be a leading indicator of these patients likelihood to achieve other post-op milestones and meet criteria for RTS more quickly. This obvious needs future study to see how grit impacts other factors like strength gains, passing RTP assessments etc.

On this episode of the HindmanCast we go back in time to the late 1950s as we catch up with former HSS Bookmobile operator and Recreation Director, Loren Kramer. Our Archive Recovery Director, Sarah Insalaco recently discovered the work of Loren while exploring the archives and was able to make contact with him to get him on the show! Don't miss the discussion about this fascinating piece of HSS history! 

What if your back pain is more than just physical? Dr. Stephen Thorp, MD — also known as “The Back Doctor” — joins The Council of Dude to explore spine health, performance, recovery, and the deeper messages our bodies send us when we're out of alignment. Stephen is a double board-certified, fellowship-trained physician who studied at Yale, Weill Cornell, HSS, and Sloan Kettering. He currently practices in Westchester County, NY, helping athletes and everyday folks move and live better. This one's about posture, pain, and purpose. Don't miss it.

On this episode of DGTL Voices, Ed interviews Lou Shapiro, CEO Emeritus of HSS. Ed and Lou discuss the importance of values, gratitude, and a helper's mindset in leadership. Lou shares his insights on creating a successful organizational culture, and his current endeavors post-retirement. "Lead with your heart, brain, and soul."

In this episode of the Wealth Planning for the Modern Physician podcast, host David Mandell sits down with two highly respected medical leaders—Dr. Mark Figgie, Chief Emeritus of the Surgical Arthritis Service at the Hospital for Special Surgery (HSS), and Dr. Joel Press, Physiatrist-in-Chief at HSS—to explore their personal and professional journeys in medicine. Dr. Press shares how his diverse early experiences led him to physiatry, while Dr. Figgie recounts his balance between science, business, and a lifelong pursuit of education, including earning an MBA during his fellowship. The conversation shifts into a discussion of mentorship at the Hospital for Special Surgery, where both physicians have played key roles in developing a cross-disciplinary mentorship model to support younger doctors. Their focus extends beyond clinical guidance to include career development, personal financial planning, and wellness—areas often overlooked in traditional medical training. This approach fosters institutional collaboration and a stronger culture at HSS. Finally, the episode dives into physicians' relationships with industry. Dr. Figgie offers candid advice on contracts, intellectual property rights, and ethical considerations when working with device manufacturers. He emphasizes the importance of legal review and staying true to what benefits patients. Dr. Press adds insight into personal financial trust, suggesting that doctors build a "board of directors" for trusted guidance. The episode closes with a preview of future initiatives aimed at supporting physicians earlier in their careers through financial education and mentorship. Key Insights: Dr. Press discovered physiatry through a unique summer program, showing the value of early exposure to diverse specialties. Dr. Figgie pursued an MBA during fellowship, believing in the power of financial literacy for physicians. Mentorship at HSS now includes financial, administrative, and personal development components—not just clinical. A cross-specialty mentorship program allows different departments (e.g., orthopedics and radiology) to learn from one another. Many young physicians lack basic financial planning tools, leading to under-preparedness later in their careers. HSS has created a repository of recorded educational sessions covering mortgages, insurance, investing, and more. Dr. Figgie cautions against blindly signing industry contracts without legal review, especially when IP is involved. Relationships with medical device companies often include consulting, design input, or teaching—but require transparency. Dr. Press emphasizes the importance of building a trusted "personal board of directors" to help with life and career decisions. Future initiatives at HSS may include subsidized financial checkups for new physicians to kickstart long-term planning. Learn more, including additional show notes, links, and detailed key takeaways, by visiting physicianswealthpodcast.com. Click here to get your FREE copy of our latest book, Wealth Strategies for Today's Physician!

In this episode of HSS Presents, Dr. Kyle Kunze, chief orthopedic surgery resident at Hospital for Special Surgery, sits down with Dr. Ayoosh Pareek, orthopedic surgeon and Medical Director of Artificial Intelligence and Digital Health at HSS. Together, they explore the evolving role of AI in musculoskeletal care—from automating clinical workflows to enhancing diagnostic capabilities—and discuss how physicians are uniquely positioned to guide ethical and effective AI integration into patient care. The conversation spans current applications such as ambient scribe technology, predictive analytics, and AI-driven patient triage, as well as long-term possibilities like agentic AI and robotics. Drs. Kunze and Pareek also examine challenges around trust, explainability, and research integrity, offering insights into how clinicians and data scientists can collaborate to ensure AI tools are both safe and impactful. This episode previews the upcoming special edition of HSS Journal, guest edited by Dr. Kunze, focused on artificial intelligence and digital health in orthopedic practice.

Today's episode is going to focus on management of patellar instability – including nonsurgical treatment, MPFL reconstruction techniques and the addition of other procedures including trochleoplasty and osteotomies. We are joined today by two outstanding guests!  Dr. Miho Tanaka is a Professor of Orthopedic Surgery at Harvard Medical School and the Director of the women sports medicine program at Mass General Brigham.  She is also the head team physician for the New England Revolution and team physician for the Boston Red Sox, Boston ballet and Boston Glory.Dr. Beth Shubin Stein is an orthopaedic surgeon at the Hospital for Special Surgery and Professor of Orthopaedic Surgery at Weill Cornell Medical College. She is also the Co-Director of the women's sports medicine center at HSS and the Director of the Patellofemoral Center at HSS.So, without further ado, let's get to the Field House!

In this episode of HSS Presents, Dr. Samuel A. Taylor, M.D., a sports medicine and shoulder surgery specialist at HSS, hosts an in‐depth discussion on long head of biceps tendon injuries with his esteemed colleagues—mentor Dr. Stephen J. O'Brien, MD, MBA, Dr. James "Beamer" Carr II, and Dr. Sri Pinnamaneni, M.D. The panel delves into the complexities of diagnosing and managing pathology within the biceps–labrum complex. They share personal anecdotes and historical insights that trace the evolution of treatment. Emphasizing that no imaging study can replace a thorough physical exam, the experts detail essential maneuvers and discuss the utility of ultrasound-guided diagnostic injections to pinpoint the true pain generator. With lively debate over whether to be a “biceps lover” or a “biceps killer,” this conversation offers valuable clinical pearls and practical strategies for shoulder surgeons navigating one of the most nuanced areas in sports medicine.

Our guest this week is an expert in the use of words as a surf columnist, writer, editor, digital marketer, copywriter and editorial content creator, with a Bachelor of Arts in English, we are sure to be corrected throughout this interview for the incorrect use of words!! Before becoming the Editor in Chief of Surfer Magazine, launching Red Bull Surfing, and working for folks like ESPN and NBC, he was writing Surfline's reports and recording their 976-SURF phone reports in the late ‘90s. He has been the Senior Editor for The Surfers Journal and World Surf League. He's been a copywriter for Quiksilver, Roxy, and Rip Curl. We welcome to the show (an HSS alumni) Mr. Jake Howard.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.